Eric Konofal

Eric Konofal

Auto-generated profile, based on publicly available information

Eric Konofal

Pediatric Sleep Disorders Center, Robert Debré Hospital, Paris, France

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in American Journal of Psychiatry
Verified
Journal Article
Closed access
ESEdmund Sonuga-Barke
Edmund Sonuga-Barke
DBDaniel Brandeis
Daniel Brandeis
SCSamuele Cortese
Samuele Cortese
DDDavid Daley
David Daley
MFMaite Ferrin
Maite Ferrin
EGEuropean ADHD Guidelines Group
European ADHD Guidelines Group

9 April 2002 in Neurology
Verified
Journal Article
Closed access
PDF file
IAI. Arnulf
I. Arnulf
EKE. Konofal
E. Konofal
MMM. Merino–Andreu
M. Merino–Andreu
JHJ. L. Houeto
J. L. Houeto
VMV. Mesnage
V. Mesnage
YAY. Agid
Y. Agid
Objective: To investigate the potential causes of excessive daytime sleepiness in patients with PD—poor sleep quality, abnormal sleep–wakefulness control, and treatment with dopaminergic agents. Methods: The authors performed night-time polysomnography and daytime multiple sleep latency tests in 54 consecutive levodopa-treated patients with PD referred for sleepiness, 27 of whom were also receiving dopaminergic agonists. Results: Sleep latency was 6.3 ± 0.6 minutes (normal >8 minutes), and the Epworth Sleepiness score was 14.3 ± 4.1 (normal 15/h; range 15.1 to 50.0). Severity of sleepiness was weakly correlated with Epworth Sleepiness score (r = −0.34) and daily dose of levodopa (r = 0.30) but not with dopamine-agonist treatment, age, disease duration, parkinsonian motor disability, total sleep time, periodic leg movement, apnea–hypopnea, or arousal indices. Conclusions: In patients with PD preselected for sleepiness, severity of sleepiness was not dependent on nocturnal sleep abnormalities, motor and cognitive impairment, or antiparkinsonian treatment. The results suggest that sleepiness—sudden onset of sleep—does not result from pharmacotherapy but is related to the pathology of PD.

1 June 2016 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Open access
SCSamuele Cortese
Samuele Cortese
MFMaite Ferrin
Maite Ferrin
DBDaniel Brandeis
Daniel Brandeis
MHMartin Holtmann
Martin Holtmann
PAPascal Aggensteiner
Pascal Aggensteiner
AZAlessandro Zuddas
Alessandro Zuddas
We performed meta-analyses of randomized controlled trials to examine the effects of neurofeedback on attention-deficit/hyperactivity disorder (ADHD) symptoms and neuropsychological deficits in children and adolescents with ADHD. We searched PubMed, Ovid, Web of Science, ERIC, and CINAHAL through August 30, 2015. Random-effects models were employed. Studies were evaluated with the Cochrane Risk of Bias tool. We included 13 trials (520 participants with ADHD). Significant effects were found on ADHD symptoms rated by assessors most proximal to the treatment setting, that is, the least blinded outcome measure (standardized mean difference [SMD]: ADHD total symptoms = 0.35, 95% CI = 0.11-0.59; inattention = 0.36, 95% CI = 0.09-0.63; hyperactivity/impulsivity = 0.26, 95% CI = 0.08-0.43). Effects were not significant when probably blinded ratings were the outcome or in trials with active/sham controls. Results were similar when only frequency band training trials, the most common neurofeedback approach, were analyzed separately. Effects on laboratory measures of inhibition (SMD = 0.30, 95% CI = -0.10 to 0.70) and attention (SMD = 0.13, 95% CI = -0.09 to 0.36) were not significant. Only 4 studies directly assessed whether learning occurred after neurofeedback training. The risk of bias was unclear for many Cochrane Risk of Bias domains in most studies. Evidence from well-controlled trials with probably blinded outcomes currently fails to support neurofeedback as an effective treatment for ADHD. Future efforts should focus on implementing standard neurofeedback protocols, ensuring learning, and optimizing clinically relevant transfer.

1 December 2004 in Archives of Pediatrics & Adolescent Medicine
Verified
Journal Article
Open access
PDF file
EKEric Konofal
Eric Konofal
MLMichel Lecendreux
Michel Lecendreux
IAIsabelle Arnulf
Isabelle Arnulf
MMMarie-Christine Mouren
Marie-Christine Mouren
Background Iron deficiency causes abnormal dopaminergic neurotransmission and may contribute to the physiopathology of attention-deficit/hyperactivity disorder (ADHD). Objective To evaluate iron deficiency in children with ADHD vs iron deficiency in an age- and sex-matched control group. Design Controlled group comparison study. Setting Child and Adolescent Psychopathology Department in European Pediatric Hospital, Paris, France. Patients Fifty-three children with ADHD aged 4 to 14 years (mean ± SD, 9.2 ± 2.2 years) and 27 controls (mean ± SD, 9.5 ± 2.8 years). Main Outcome Measures Serum ferritin levels evaluating iron stores and Conners’ Parent Rating Scale scores measuring severity of ADHD symptoms have been obtained. Results The mean serum ferritin levels were lower in the children with ADHD (mean ± SD, 23 ± 13 ng/mL) than in the controls (mean ± SD, 44 ± 22 ng/mL;P < .001). Serum ferritin levels were abnormal (<30 ng/mL) in 84% of children with ADHD and 18% of controls (P < .001). In addition, low serum ferritin levels were correlated with more severe general ADHD symptoms measured with Conners’ Parent Rating Scale (Pearson correlation coefficient,r = −0.34;P < .02) and greater cognitive deficits (r = −0.38;P < .01). Conclusions These results suggest that low iron stores contribute to ADHD and that ADHD children may benefit from iron supplementation.

1 August 2005 in SLEEP
Verified
Journal Article
Open access
PDF file
SCSamuele Cortese
Samuele Cortese
EKEric Konofal
Eric Konofal
MLMichel Lecendreux
Michel Lecendreux
IAIsabelle Arnulf
Isabelle Arnulf
MMMarie-Christine Mouren
Marie-Christine Mouren
BBBernardo Dalla Bernardina
Bernardo Dalla Bernardina
To review evidence on the association between restless legs syndrome (RLS) and attention-deficit/hyperactivity disorder (ADHD), to discuss the hypothetical mechanisms underlying this association, and to consider the potential interest for common pharmacologic treatments of RLS and ADHD when co-occurring. A PubMed search. In clinical samples, up to 44% of subjects with ADHD have been found to have RLS or RLS symptoms, and up to 26% of subjects with RLS have been found to have ADHD or ADHD symptoms. Several mechanisms may explain this association. Sleep disruption associated with RLS might lead to inattentiveness, moodiness, and paradoxical overactivity. Diurnal manifestations of RLS, such as restlessness and inattention, might mimic ADHD symptoms. Alternatively, RLS might be comorbid with idiopathic ADHD. Subjects with RLS and a subset of subjects with ADHD might share a common dopamine dysfunction. Limited evidence suggests that some dopaminergic agents, such as levodopa/carbidopa, pergolide, and ropinirole, may be effective in children with RLS associated with ADHD symptoms. Although still limited, evidence from clinical studies demonstrates an association between RLS and ADHD or ADHD symptoms. Further clinical studies using standard criteria and procedures are needed to better estimate the degree of association. Epidemiologic studies are required to assess the relationship between ADHD and RLS symptoms in nonclinical samples. Further investigations should address the mechanisms underlying the relationship between RLS and ADHD. Several dopaminergic agents seem to be promising treatment for RLS associated with ADHD symptoms. To date, however, the absence of randomized and blinded controlled studies does not allow evidence-based recommendations.

28 May 2008 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Closed access
SCSamuele Cortese
Samuele Cortese
MAMarco Angriman
Marco Angriman
CMClaudio Maffeis
Claudio Maffeis
PIPascale Isnard
Pascale Isnard
EKEric Konofal
Eric Konofal
MMMarie-Christine Mouren
Marie-Christine Mouren
Recent studies suggest a possible comorbidity between Attention-Deficit/Hyperactivity Disorder (ADHD) and obesity. To gain insight into this potential association, we performed a systematic review of the literature excluding case reports, non-empirical studies, and studies not using ADHD diagnostic criteria. Empirically based evidence suggests that obese patients referred to obesity clinics may present with higher than expected prevalence of ADHD. Moreover, all reviewed studies indicate that subjects with ADHD are heavier than expected. However, data on the prevalence of obesity in subjects with ADHD are still limited. As for the mechanisms underlying the potential association between ADHD and obesity, ADHD might lead to obesity via abnormal eating behaviors, impulsivity associated with binge eating might contribute to ADHD in obese patients, or, alternatively, both obesity and ADHD might be the expression of common underlying neurobiological dysfunctions, at least in a subset of subjects. In patients with obesity and ADHD, both conditions might benefit from common therapeutic strategies. Further empirically based studies are needed to understand the potential comorbidity between obesity and ADHD, as well as the possible mechanisms underlying this association. This might allow a more appropriate clinical management and, ultimately, a better quality of life for patients with both obesity and ADHD.